SCHEMBL4817899

SCHEMBL4817899

COCCOCCOc1ccc(C(=O)Oc2ccccc2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.66
RAB9A P51151 2/20 0.66
PKM P14618 2/20 0.55
PARP10 Q53GL7 2/20 0.53
KMT2A Q03164 5/20 0.50
LMNA P02545 4/20 0.50
L3MBTL1 Q9Y468 4/20 0.50
KDM4E B2RXH2 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
HSP90AA1 P07900 1/20 0.50
RARB P10826 1/20 0.48
MEN1 O00255 2/20 0.48
PRSS1 P07477 1/20 0.47
ACR P10323 1/20 0.47
NPC1 O15118 2/20 0.47
MAPK1 P28482 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27971808 0.96 MAPT (0.71) MAPTRAB9APKMPARP10KMT2A
SCHEMBL24292398 0.89 LMNA (0.56) MAPTRAB9AKMT2ALMNAL3MBTL1
SCHEMBL4814098 0.88 MAPT (0.72) MAPTRAB9APKMPARP10KMT2A
SCHEMBL4818073 0.87 MAPT (0.63) MAPTRAB9APKMPARP10KMT2A
SCHEMBL21063817 0.83 MAPT (0.80) MAPTRAB9AKMT2ALMNAL3MBTL1
SCHEMBL5706230 0.82 KMT2A (0.70) MAPTRAB9AKMT2ALMNAPRSS1
SCHEMBL9374029 0.82 MAPT (0.59) MAPTRAB9APKMPARP10KMT2A
SCHEMBL9220806 0.82 MAPT (0.54) MAPTRAB9AKMT2ALMNAL3MBTL1
SCHEMBL9019628 0.82 RARB (0.68) MAPTRAB9APKML3MBTL1RARB
SCHEMBL13448825 0.82 RARB (0.68) MAPTRAB9APKML3MBTL1RARB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1740579-B1 TRICYCLIC PYRAZOLE KINASE INHIBITORS ABBVIE INC (US) 2015-08-19 EP disclosed
US-7468371-B2 Tricyclic pyrazole kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-12-23 US disclosed
EP-1740579-A1 TRICYCLIC PYRAZOLE KINASE INHIBITORS Abbott Laboratories (US) 2007-01-10 EP disclosed
US-20060014816-A1 Tricyclic pyrazole kinase inhibitors ABBVIE INC. 2006-01-19 US disclosed
WO-2005095387-A1 TRICYCLIC PYRAZOLE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2005-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060014816-A1 Tricyclic pyrazole kinase inhibitors PRKDC, PRKACA, PIK3C3 MAPT 2427/4885RAB9A 2541/4885PKM 588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.